406 related articles for article (PubMed ID: 32723468)
21. Convalescent plasma treatment for COVID-19: Tempering expectations with the influenza experience.
Subbarao K; Mordant F; Rudraraju R
Eur J Immunol; 2020 Oct; 50(10):1447-1453. PubMed ID: 32886952
[TBL] [Abstract][Full Text] [Related]
22. Rapid recovery of a SARS-CoV-2-infected X-linked agammaglobulinemia patient after infusion of COVID-19 convalescent plasma.
Mira E; Yarce OA; Ortega C; Fernández S; Pascual NM; Gómez C; Alvarez MA; Molina IJ; Lama R; Santamaria M
J Allergy Clin Immunol Pract; 2020 Sep; 8(8):2793-2795. PubMed ID: 32652231
[No Abstract] [Full Text] [Related]
23. Plasma Therapies and Parabiosis in the COVID-19 Era.
Calvani R; Picca A; Landi F; Marzetti E
J Am Med Dir Assoc; 2020 Jul; 21(7):994-995. PubMed ID: 32674834
[No Abstract] [Full Text] [Related]
24. Coronavirus drugs: Using plasma from recovered patients as a treatment for COVID-19.
Alzoughool F; Alanagreh L
Int J Risk Saf Med; 2020; 31(2):47-51. PubMed ID: 32310190
[TBL] [Abstract][Full Text] [Related]
25. Plasma from donors convalescent from SARS-CoV-2 infection-A matter of priorities.
Farrugia A
Transfus Clin Biol; 2020 Aug; 27(3):167-168. PubMed ID: 32563550
[No Abstract] [Full Text] [Related]
26. Analysis of COVID-19 convalescent plasma for SARS-CoV-2 IgG using two commercial immunoassays.
DomBourian MG; Annen K; Huey L; Andersen G; Merkel PA; Jung S; Dominguez SR; Knight V
J Immunol Methods; 2020 Nov; 486():112837. PubMed ID: 32828791
[TBL] [Abstract][Full Text] [Related]
27. Position paper on the preparation of immune plasma to be used in the treatment of patients with COVID-19.
Accorsi P; Berti P; de Angelis V; De Silvestro G; Mascaretti L; Ostuni A;
Transfus Apher Sci; 2020 Aug; 59(4):102817. PubMed ID: 32532691
[TBL] [Abstract][Full Text] [Related]
28. A Randomized Open label Phase-II Clinical Trial with or without Infusion of Plasma from Subjects after Convalescence of SARS-CoV-2 Infection in High-Risk Patients with Confirmed Severe SARS-CoV-2 Disease (RECOVER): A structured summary of a study protocol for a randomised controlled trial.
Janssen M; Schäkel U; Djuka Fokou C; Krisam J; Stermann J; Kriegsmann K; Haberbosch I; Novotny JP; Weber S; Vehreschild M; Bornhäuser M; Bullinger L; Schmitt M; Liebregts T; Dreger P; Lorenz HM; Plaszczyca A; Bartenschlager R; Müller B; Kräusslich HG; Halama N; Jäger D; Schlenk RF; Leo A; Meuer S; Weigand MA; Motsch J; Merle U; Denkinger CM; Müller-Tidow C
Trials; 2020 Oct; 21(1):828. PubMed ID: 33023671
[TBL] [Abstract][Full Text] [Related]
29. Testing an Old Therapy Against a New Disease: Convalescent Plasma for COVID-19.
Rubin R
JAMA; 2020 Jun; 323(21):2114-2117. PubMed ID: 32352484
[No Abstract] [Full Text] [Related]
30. Deployment of convalescent plasma for the prevention and treatment of COVID-19.
Bloch EM; Shoham S; Casadevall A; Sachais BS; Shaz B; Winters JL; van Buskirk C; Grossman BJ; Joyner M; Henderson JP; Pekosz A; Lau B; Wesolowski A; Katz L; Shan H; Auwaerter PG; Thomas D; Sullivan DJ; Paneth N; Gehrie E; Spitalnik S; Hod EA; Pollack L; Nicholson WT; Pirofski LA; Bailey JA; Tobian AA
J Clin Invest; 2020 Jun; 130(6):2757-2765. PubMed ID: 32254064
[TBL] [Abstract][Full Text] [Related]
31. Editorial: Information on the COVID-19 Pandemic continued.
Rock G
Transfus Apher Sci; 2020 Aug; 59(4):102854. PubMed ID: 32660893
[No Abstract] [Full Text] [Related]
32. Treatment of COVID-19 with convalescent plasma: lessons from past coronavirus outbreaks.
Wooding DJ; Bach H
Clin Microbiol Infect; 2020 Oct; 26(10):1436-1446. PubMed ID: 32791241
[TBL] [Abstract][Full Text] [Related]
33. Convalescent plasma for covid-19.
Estcourt LJ; Roberts DJ
BMJ; 2020 Sep; 370():m3516. PubMed ID: 32933945
[No Abstract] [Full Text] [Related]
34. Position paper on the preparation of immune plasma to be used in the treatment of patients with COVID-19.
Accorsi P; Berti P; de Angelis V; De Silvestro G; Mascaretti L; Ostuni A;
Blood Transfus; 2020 May; 18(3):163-166. PubMed ID: 32453687
[TBL] [Abstract][Full Text] [Related]
35. [Use of convalescent plasma for COVID-19 treatment. History and evidence].
McAllister F; Mantegazza A; Garzón F; Rotbaum V; Remondino G; Vazquez Larsson M; Geffner J; Rabinovich GA; Bover L
Medicina (B Aires); 2020; 80 Suppl 3():82-86. PubMed ID: 32658853
[No Abstract] [Full Text] [Related]
36. Anti-SARS-CoV-2 virus antibody levels in convalescent plasma of six donors who have recovered from COVID-19.
Zhang L; Pang R; Xue X; Bao J; Ye S; Dai Y; Zheng Y; Fu Q; Hu Z; Yi Y
Aging (Albany NY); 2020 Apr; 12(8):6536-6542. PubMed ID: 32320384
[TBL] [Abstract][Full Text] [Related]
37. Convalescent plasma therapy for COVID-19: a tried-and-true old strategy?
Xi Y
Signal Transduct Target Ther; 2020 Sep; 5(1):203. PubMed ID: 32934211
[No Abstract] [Full Text] [Related]
38. Improved clinical symptoms and mortality among patients with severe or critical COVID-19 after convalescent plasma transfusion.
Xia X; Li K; Wu L; Wang Z; Zhu M; Huang B; Li J; Wang Z; Wu W; Wu M; Li W; Li L; Cai Y; Bosco B; Zhong A; Liu X; Lv T; Gan Z; Chen G; Pan Y; Liu C; Zhang K; Xu X; Wang C; Wang Q
Blood; 2020 Aug; 136(6):755-759. PubMed ID: 32573724
[TBL] [Abstract][Full Text] [Related]
39. COVID-19 convalescent plasma donor recruitment: beware the Faustian bargains.
Gniadek TJ; Donnersberger D
Transfusion; 2020 Jul; 60(7):1643-1644. PubMed ID: 32428966
[No Abstract] [Full Text] [Related]
40. Convalescent plasma to treat COVID-19.
Bloch EM
Blood; 2020 Aug; 136(6):654-655. PubMed ID: 32761219
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
